Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Cancer
- Disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 306836
Compound means ATT-11T together with all analogs, derivatives, metabolites, stereoisomers, polymorphs, formulations, mixtures, or compositions thereof, and any existing or future improved or modified versions of the foregoing developed by or on behalf of Licensee, its affiliates or sublicensees.
IPSCIO Record ID: 372536
L-Nucleoside Dimer Compounds and Therapeutic Uses;
Nucleoside Analogs and Uses Against Parasitic Infection;
Novel Nucleoside Analogs and Uses in Treating Plasmodium Falciparum; and,
Novel Nucleoside Analogs and Uses in Treating Diseases.
Licensor has certain Patent Rights and Know-how relating to a family of proprietary compounds capable of selectively delivering therapeutic drugs to diseased cells.
Compounds evolving from Licensor’s L-nucleoside conjugate technology take advantage of cell membrane changes that differentiate cancerous cells from healthy cells. This anomalous characteristic of cancer cell membranes presents a unique opportunity for targeting these cells with new products which are uniquely designed cytotoxic nucleosides that selectively enter cancerous cells.
IPSCIO Record ID: 372690
AU-011, covalently conjugates approximately 200 molecules of an infrared light-activated molecule, IRDye® 700DX, to the VLP (Virus-Like Particles) in a way that is designed not to interfere with tumor binding. AU-011 consists of an HPV-derived VLP conjugated to hundreds of infrared laser-activated molecules. The VDC is designed in a way that prevents the conjugation from interfering with tumor binding enabling its selectivity to specifically modified HSPGs on tumor cells but not to normal cells. Laser activation of AU-011 is designed to result in precise tumor cell killing with minimal damage to surrounding healthy tissues. In the absence of AU-011 activation or binding to the tumor cell membrane, there is no cytotoxic effect. Multiple laser treatments, following a single dose of AU-011, increase antitumor activity because of the reoxygenation of the tumor and the photostability of AU-011. Finally, acute necrosis triggers immunogenic cell death leading to the generation of an adaptive, long-term antitumor immune response.
VDCs are a novel class of drugs with a dual mechanism of action that promotes cancer cell death by both the delivery of the cytotoxic payload to generate acute necrosis and by activating a secondary immune mediated response. VDCs are analogous to ADCs, another technology that employs a targeting moiety and a cytotoxic payload.
IPSCIO Record ID: 263763
Licensor grants to Licensee, to the extent Licensor is legally able to do so, a non-exclusive, sublicensable, license in the Territory under such issued letters patent for Licensee to develop, make, have made, use, sell, offer for sale or import Compounds and Products in the Territory.
For the Covenants/Companion Diagnostic, Licensor grants a non-exclusive license, with the right to grant sublicenses, under Licensor Patent Rights, Licensor Know-How, and Companion Diagnostic Trademarks to market and promote the Companion Diagnostic in the Field in the Territory for use in connection with the Product and use the Companion Diagnostic in any way necessary or reasonably useful in order for Licensee to exercise the license granted by Licensor.
This agreement is to develop and commercialize a novel investigational therapeutic candidate vintafolide (EC145).
Vintafolide is a proprietary, injectable, conjugate consisting of folate (vitamin B9) linked to a potent vinca alkaloid chemotherapy agent, desacetylvinblastine monohydrazide (DAVLBH).
Etarfolatide is a folate-targeted molecular imaging agent that is being developed as a noninvasive method to identify tumors that over-express folate receptors.
Product(s) means any pharmaceutical or biological preparation.
Vintafolide is designed to preferentially target the chemotherapy agent to fast growing cancer cells that actively take up folate via the folate receptor. The folate receptor is expressed in a wide variety of cancers including ovarian, NSCLC, breast, colon and kidney.
IPSCIO Record ID: 248277
The Institute hereby grants to Licensor an exclusive option to exclusively license any and all Improvement Inventions and Non-Improvement Inventions (the Option).
U.S. Patent Application #61/392,296 – Small Molecules Inhibiting Oncoprotein MYC
U.S. Patent Application #61/423,832 – Small Molecules inhibiting Oncoprotein MYC
ANTIMYCON
· Drug summary MYC inhibitor.
· Indications Drugs for treatment of a broad range of solid tumors (breast, prostate, colon, non-small cell lung carcinoma, etc.) and hematological malignancies (various types of leukemia and lymphoma).
· Mechanism of action CBLC-M compounds were generated to selectively target and inactivate oncoproteins of the Myc family, which are frequently upregulated in tumor cells. Although Myc has long been recognized as a highly attractive target for anti-cancer treatment, there are no experimental
or approved drugs targeting this transcription factor. CBLC-M compounds target Myc family proteins with a high degree of specificity and cause their selective degradation. This mechanism of action is translated into both a direct tumor-suppressive effect and increased susceptibility of tumor cells to conventional chemotherapeutic drugs. Combining CBLC-M with such drugs as doxorubicin, 5FU, irinotecan and others within composite nanoparticles will result in improved anti-tumor effects due to precise targeted drug delivery that will concentrate the synergistic effects of the combined compounds on the tumor cells while reducing toxicity to normal cells.
